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Abstract
Background: Long-term outcome in multiple sclerosis (MS) depends on early treatment. In patients with acute
optic neuritis (ON), an early inflammatory event, we investigated markers in cerebrospinal fluid (CSF), which may
predict a diagnosis of MS.
Methods: Forty patients with acute ON were recruited in a prospective population-based cohort with median 29
months (range 19–41) of follow-up. Paired CSF and serum samples were taken within 14 days (range 2–38), prior to
treatment. Prospectively, 16/40 patients were by a uniform algorithm diagnosed with MS (MS-ON) and 24 patients
continued to manifest isolated ON (ION) during follow-up. Levels of cytokines and neurofilament light chain (NF-L)
were measured at the onset of acute ON and compared to healthy controls (HC). Significance levels were corrected for
multiple comparisons (“q”). The predictive value of biomarkers was determined with multivariable prediction models
using nomograms.
Results: CSF TNF-α, IL-10, and CXCL13 levels were increased in MS-ON compared to those in ION patients (q = 0.021,
0.004, and 0.0006, respectively). MS-ON patients had increased CSF pleocytosis, IgG indices, and oligoclonal bands
(OCBs) compared to ION (q = 0.0007, q = 0.0058, and q = 0.0021, respectively). CSF levels of IL-10, TNF-a, IL-17A, and
CXCL13 in MS-ON patients correlated with leukocyte counts (r > 0.69 and p < 0.002) and IgG index (r > 0.55, p < 0.037).
CSF NF-L levels were increased in ON patients compared to those in HC (q = 0.0077). In MS-ON, a progressive increase
in NF-L levels was observed at 7 to 14 days after disease onset (r = 0.73, p < 0.0065). Receiver-operating characteristic
(ROC) curves for two multivariable prediction models were generated, with IL-10, CXCL13, and NF-L in one (“candidate”)
and IgG index, OCB, and leukocytes in another (“routine”). Area under the curve was 0.89 [95% CI 0.77–1] and 0.86 [0.74–
0.98], respectively. Predictions of the risk of MS diagnosis were illustrated by two nomograms.
Conclusions: CSF TNF-α, IL-10, CXCL13, and NF-L levels were associated with the development of MS, suggesting that
the inflammatory and neurodegenerative processes occurred early. Based on subsequent diagnosis, we observed a high
predictive value of routine and candidate biomarkers in CSF for the development of MS in acute ON. The nomogram
predictions may be useful in the diagnostic work-up of MS.
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Introduction
Optic neuritis (ON) is an inflammatory optic neur-
opathy, which may occur as an early manifestation of
multiple sclerosis (MS) [1]. ON is believed to be
immune-mediated and results from the destruction of
the myelin sheath and nerve fibers, resulting in impaired
vision or blindness [2]. Antibodies with specificity for
myelin oligodendrocyte glycoprotein (MOG) are impli-
cated in ON, as well as in ON associated with neuromy-
elitis optica spectrum disorder (NMOSD) in cases where
immunoglobulin (Ig) G antibodies against the water
channel aquaporin-4 are undetectable [3–6]. The predi-
lection for the optic nerve in MS may be explained by
regional differences in blood-brain barrier (BBB) perme-
ability. Significant risk factors for the transition of ON
to MS routinely used in clinical practice are the presence
of brain lesions on MRI and cerebrospinal fluid
(CSF)-restricted oligoclonal bands (OCBs). These repre-
sent intrathecally produced IgG of unknown specificity
[7, 8]. Apart from OCBs, alterations of the levels of
interleukin (IL)-10 produced by naïve and/or regulatory
B cells and the chemokine, CXCL13, which is a key
regulator of B cell recruitment, have been reported in
MS patients [9–11]. These findings suggest that B cells
play a role in the pathogenesis of MS, although their
importance in MS development has not yet been
determined.
Neurofilament light chain (NF-L) is a major structural
component of neurons. Increased levels of NF-L in CSF
have been suggested to be a marker of axonal damage in
MS [12]. The implications of early changes of NF-L
levels in acute ON and its potential predictive value for
the subsequent conversion to MS are unexplored. Fur-
thermore, the relation between intrathecal inflammation
and neurodegeneration in acute ON is incompletely
understood. We propose that markers of inflammation
and of neurodegeneration (a) may differ between
patients with MS-related ON and patients with ON un-
related to MS and (b) may predict development of MS
in patients with acute ON.
Materials and methods
Study design and patients
Patients with acute ON originated from a
population-based prospective study with clinical follow-up
performed 2014–2016 in the Region of Southern Denmark
[13, 14]. The diagnosis of ON was obtained by independ-
ent neurological and ophthalmological examination as pre-
viously described based on a uniform algorithm [13, 14].
The neurologist and ophthalmologist were masked to re-
sults from autoantibody and cytokine/chemokine analysis,
and the laboratory analyses were performed blinded to the
clinical status of patients [14]. Patients were excluded if
they had been diagnosed previously with MS or NMOSD.
AQP4-IgG was measured with a recombinant immuno-
fluorescence assay using HEK293 cells transfected with re-
combinant human full-length AQP4 gene and re-evaluated
by means of an in-house cell-based assay [14]. MOG-IgG
was determined by two cell-based assays employing fixed
and live HEK293 cells, respectively, transfected with
full-length human DNA [3, 6]. MS was diagnosed accord-
ing to the 2010 MS criteria [8]. Forty patients presenting
with acute ON prior to treatment and a median follow-up
time after onset of 29months (range 19–41) were included
in the study. We tested and found no indication of im-
munological differences between males and females (not
shown).
CSF samples were collected from 12 age-matched sub-
jects assessed because of sudden transient headache
without trauma or infection and where all subsequent
investigations were normal. These individuals were
considered healthy controls (HC) [15].
Sample storage and handling
Venous blood and CSF from 40 patients were collected
within 38 days of ON onset (median, 14 days; range 2–38).
For IgG and albumin ratios, EDTA plasma was prepared
and analyzed directly. CSF was sampled and stored ac-
cording to international research standards [1]. Briefly, for
quantification of IL-1β, IL-6, IL-10, IL-17A, tumor necro-
sis factor (TNF)-α, and TNF-related apoptosis-inducing
ligand (TRAIL), CSF was collected, centrifuged immedi-
ately, cooled to 4 °C for 2 h, and stored at − 20 °C for up to
1month and then at − 80 °C until analysis. Serum was
isolated following clot formation at ambient temperature
and frozen as described for CSF.
Interferon (IFN)-α, IFN-β, and CXCL13 concentrations
were determined on an aliquot of the CSF and serum that
had been frozen at − 80 °C immediately following centrifu-
gation. Samples were thawed once for aliquoting prior to
analysis, except for CXCL13 (one additional thawing cycle).
Immunochemical and cytological parameters
Routine diagnostic analyses were carried out at the De-
partment of Biochemistry and Immunology, Vejle Hos-
pital, being accredited by Danish Accreditation Fund
(DANAK) according to the ISO 15189 standard that spe-
cifies requirements for quality and competence in medical
laboratories. IgG and albumin were measured on a Cobas
8000C instrument (Roche, Basel, Switzerland), oligoclonal
bands (OCBs) on a Hydrasys instrument (Sebia, Surrey,
UK), and leukocytes on a Sysmex XN-9000 instrument
(Sysmex Europe, Norderstadt, Germany).
Immunoassay measurements
IL-1β, IL-6, IL-10, IL-17A, TNF-α, TRAIL, and NF-L
were measured using Simoa HD-1 digital enzyme-linked
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immunosorbent assay (ELISA) (Quanterix, Lexington,
MA, USA).
CXCL13 and INF-α/β concentrations were determined
using ELISAs (Euroimmun, Lübeck, Germany and PBL
Assay Science, NJ, USA, respectively) in the Department
of Clinical Immunology, Odense University Hospital, also
accredited according to the ISO 15189 standard. Lower
cutoff sensitivity of the CXCL13 assay was set to 10 pg/ml,
according to the manufacturer’s instructions [16].
Statistical analysis
Association analysis
Prism 7 (GraphPad Software, La Jolla, CA) was used for
generating comparisons and correlation analyses with a
significance level of 5%. Fisher’s exact test was used to
test for differences regarding frequency distributions
(sex and OCBs). Continuous variable data was analyzed
using the nonparametric Kruskal-Wallis test. Results de-
scribed in the text are given as “median [25th–75th percen-
tiles]” unless otherwise clearly stated. CSF-to-serum ratio of
cytokines was normalized to albumin ratio and similarly
compared by the Kruskal-Wallis test. To account for mul-
tiple testing, these analyses were followed by false discovery
rate adjustment (alpha = 0.05) of p values, and correspond-
ing q values were reported unless clearly stated [17]. Spear-
man correlations were estimated and tested for being
identical to 0 without further p value adjustment. This ap-
proach for reducing false positives was chosen due to the
explorative nature of the study.
Predictive modeling
R version 3.3 (R Core Team at R Foundation for Statis-
tical Computing, Vienna, Austria) was used for extended
analyses of the conversion of isolated optic neuritis
(ION) to multiple sclerosis in relation to optic neuritis
(MS-ON). Here, logistic regression modeling was per-
formed, including receiver-operating characteristic
(ROC) area under curve (AUC) calculations. For uni-
and multivariate model assessment, we reported on likeli-
hood ratios, overall p values, and McFadden’s adjusted R2,
and for multivariate models also the Hosmer-Lemeshow’s
goodness-of-fit test is reported. Since prediction perform-
ance measures such as AUCs are overly optimistic when
calculated for the same sample population as used for
model fitting, we also applied a bootstrap optimism cor-
rection based on 500 bootstrap samples. This is an
internal validation method for assessing the optimism bias
of prediction models when no validation cohort is available,
i.e., when a model is fitted and tested on the same dataset.
The approach calculates AUCapparent −Optimism=AUCcor-
rected, and is described in detail by Steyerberg [18]. When
applying this approach, we did however not account for po-
tential preselection of variables before inclusion in our mul-
tivariable prediction models, in which case the actual
optimism will likely be larger than estimated. Nomograms
as graphical output representations of the logistic regres-
sion models were made using R, and calibration plots
showing observed versus expected proportions were used
to assess calibration of the prediction models.
Results
Cohort characteristics
All 40 patients with acute ON were Caucasians with a
female to male ratio of 2:1 and a median age of 36 years
(range 16–66 years). A total of 12 patients (30%) were
diagnosed with MS (MS-ON) at the acute stage of ON
(< 2months), and four additional patients developed MS
within the first year of follow-up (giving a total of 16 pa-
tients, 40%, with MS-ON) [14]. The remaining 24 pa-
tients had a final diagnosis of isolated ON (ION). None
of the patients had detectable AQP4-IgG according to
two cell-based assays performed at two independent la-
boratories. MOG-IgG was detected in one patient at a
titer of 1:1280 [19]. There were no significant differences
between the ION and MS-ON patients as to age, gender,
or follow-up time. Median follow-up time was 30months
(range 21–41) for ION, and 28months (range 19–38) for
MS-ON (Table 1).
Routine CSF biomarkers are increased in MS-ON patients
and distinguish MS-ON from ION
CSF biomarkers were assessed at the time of the acute ON
event. ON patients were stratified based on prospective
diagnosis into ION and MS-ON and compared to HC. As
a whole, MS-ON patients showed increased levels of CSF
leukocytes (median [25th–75th percentiles] 18 [4–44.5]
versus 2.5 [1–4.8] cells/μl, respectively, q = 0.0007), they ex-
hibited OCB positivity more frequently than ION patients
(13/16 positive versus 6/24, respectively, q = 0.0021),
and had a higher IgG index (1.1 [0.56–1.82] versus 0.52
[0.49–0.59], respectively, q = 0.0052; Fig. 1a–c). Two
MS-ON patients but none with ION had albumin ratios
above the threshold of [age]/25 + 8 proposed by Hegen
and colleagues [15]. The findings suggest higher immune
reactivity in the CSF of MS-ON patients.
High intrathecal IL-10, TNF-α, and CXCL13 are associated
with a diagnosis of MS
When comparing cytokine/chemokine protein levels, we
found higher CSF levels of IL-10, TNF-α, and CXCL13
in MS-ON than in ION (IL-10, respectively, 0.27 [0.11–
1.26] vs 0.083 [0.043–0.12] pg/ml, q = 0.004, TNF-α 0.37
[0.21–0.43] vs 0.16 [0.13–0.24] pg/ml, q = 0.021, and
CXCL13 28.9 [10–75.4] vs 10 [10] pg/ml, q = 0.0006;
Fig. 2a). No differences could be detected in serum
(Fig. 2b). This indeed suggests that, although clinically in-
distinguishable, patients destined to develop MS have a
distinct CNS immune phenotype relative to ION patients.
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IL-1β, IL-6, IL-17A, and TRAIL could be detected in
all CSF samples except IL-1β and IL-17A that were un-
detectable in two samples, and levels appeared similar
between the two patient groups (Fig. 2a, b). IFN-α was
detected in serum and CSF from one ION patient while
IFN-β could be detected only in CSF from one other
ION patient (not shown).
We calculated the cytokine-specific CSF/serum ratios
normalized to albumin ratio, e.g., ([IL-10]CSF/
[IL-10]serum)/albumin ratio, to indicate whether cyto-
kines were synthesized intrathecally. Both IL-10 and
TNF-α showed significantly higher indices in MS-ON
compared to ION before false discovery rate adjustment
(p = 0.036 and 0.048, respectively). For CXCL13, only
one patient with MS-ON had detectable levels in both
serum and CSF. The seven other MS-ON patients and
two ION patients with detectable CXCL13 in CSF had
undetectable levels in serum. These findings argue in
favor of intrathecal cytokine synthesis.
Testing for correlations between intrathecal markers
for inflammation in MS-ON disclosed increased CSF
levels of IL-10, TNF-α, and CXCL13 that failed to cor-
relate with the albumin ratio, suggesting that cytokine
levels did not reflect blood/CSF barrier disruption
(Fig. 3a). In contrast, a strong correlation between each of
these cytokines and CSF leukocyte counts (Spearman r ≥
0.69 for all, p = 0.0042, p < 0.0001, and p = 0.002, respect-
ively; Fig. 3b) and IgG index could be detected (Spearman
r ≥ 0.55 for all, p = 0.001, p = 0.037, and p = 0.003, respect-
ively; Fig. 3c). IL-17A exhibited a similar pattern of correl-
ation, although not differentially expressed in MS-ON
(Fig. 2a).
Similar correlations were also found in ION patients
but were less strong (Spearman r between 0.48–0.53 and
p > 0.024 for all; Additional file 1: Figure S1), suggesting
that CNS immune processes in MS-ON are distinct
from those in ION.
CSF NF-L levels are increased in acute ON and progress in
MS-ON
Quantification of NF-L in CSF revealed higher levels in
all 40 acute ON patients compared to 11 HC (451 [224–
947] pg/ml vs 229 [161–346] pg/ml, respectively, q
= 0.0324). When stratified based on subsequent (pro-
spective) diagnosis, these elevations in NF-L were
restricted to MS-ON patients (q = 0.0077, Fig. 4a).
Moreover, when considering all ON patients
(disregarding the prospective MS-ON or ION diagnosis),
patients with CSF NF-L higher than the median (> 450
pg/ml) had more abundant CSF leukocytes than ON pa-
tients with NF-L < 450 pg/ml (10.5 cells/μl [3–42.2; n =
18] versus 2.0 [1–7.5; n = 17], p = 0.011, not shown).
There was no correlation with other inflammatory
markers. In MS-ON, but not in ION patients, a gradual
increase in CSF NF-L levels was observed in the period
Table 1 Distribution of age, sex, and follow-up time in the patient groups
N f/m Ratio Years of age, median (range) Follow-up time, median (range)
HC 12 5/7 0.7 48.0 (16–63) n.a.
ION 24 16/8 2.0 39.3 (16–67) 29.6 (21–41)
MS-ON 16 11/5 2.2 41.5 (23–52) 28.2 (19–38)
p value versus ION MS-ON ION MS-ON ION MS-ON
HC 0.175 0.250 0.219 0.368 n.a. n.a.




Fig. 1 Routine cerebrospinal fluid findings differentiate patients who later converted to multiple sclerosis at onset of optic neuritis. a Cerebrospinal
fluid (CSF) leukocyte count, b distribution of oligoclonal band (OCB) positivity and negativity and c IgG index in multiple sclerosis (MS)-related optic
neuritis (ON) (MS-ON), isolated ON (ION), and healthy controls (HC). Open circles indicate four patients that were diagnosed with MS 3 to 12months
after ON onset
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between 7 and 14 days after disease onset (Spearman r =
0.73, p = 0.0065, Fig. 4b).
Modeling of conversion of ON to MS
To assess whether it is possible to predict development of
MS-ON in the cohort of patients with ON, we employed
logistic regression utilizing one or more possible predictor
variables. Regression models based on individual parame-
ters were tested first, and optimal cutoffs for each univariate
prediction model were calculated according to the Youden
method (Additional file 2: Table S1). ROC curves for single
predictors are shown in Additional file 3: Figure S2.
A
B
Fig. 2 Intrathecal levels of TNF-α, IL-10, and CXCL13 distinguish patients who develop multiple sclerosis. Cytokines and chemokines as denoted in
a cerebrospinal fluid and b serum. Open circles indicate patients that were diagnosed with multiple sclerosis 3 to 12months after optic neuritis onset
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Next, the predictive performance of two different
combined models was tested. The model entitled “rou-
tine biomarkers” comprises parameters distinguishing
ION from MS-ON in Fig. 1. The second, “candidate bio-
markers”, contains parameters based on findings in
Figs. 2 and 4. TNF-α was not included because screening
sets of variables indicated that it explained the same vari-
ation as IL-10 and thus did not add additional informa-
tion. However, both IgG index and OCB were included in
the routine biomarker model even though the ROC curve
for leukocytes and OCB showed AUC equivalent to that
of leukocytes and IgG index (Additional file 4: Figure S4
and Additional file 5: Figure S5) because of the face valid-
ity (i.e., biological relation to MS-ON), thus potentially
providing predictive information. Routine biomarkers
comprised OCB, leukocyte count, and IgG index, while
candidate biomarkers included CSF IL-10, CXCL13, and
NF-L. These biomarker cohorts yielded AUC of 0.86
[0.74–0.98] and 0.89 [95% C.I.: 0.77–1], respectively
(Table 2 and Fig. 5; cf. Additional file 6: Figure S5 for
calibration plots). Combining these two models with six
predictors did not significantly improve AUC (0.90; 95%
CI: 0.78–1), and thus this aggregate was felt to be too
cumbersome for the clinical setting. For all three models,
Hosmer-Lemeshow’s goodness-of-fit test supported that
the prediction models fitted the data.
Because the two predictor models were generated and
tested on the same dataset, they are inherently optimis-
tic. Therefore, the optimism of each model was
estimated to obtain an optimism-corrected estimate of
the AUC. This reduced their AUC to 0.83 (routine) and
0.87 (candidate).
MS risk assessment via nomograms based on CSF
findings
Two nomograms were developed as predictive tools
based on levels of CSF biomarkers (routine and candi-
date models) useful for the estimation of a given
patient’s risk of developing MS after presenting with
acute ON (Fig. 6a, b). For each, three single predictor
variables were combined into a multivariate logistic
A B C
Fig. 3 Intrathecal immune activity in patients who develop multiple sclerosis. Cerebrospinal fluid levels of TNF-α, IL-10, IL-17A, and CXCL13 in
patients who develop multiple sclerosis (MS-ON) and their correlation with a albumin ratio, b leukocyte count, and c IgG index. Open circles
indicate patients that were diagnosed with MS 3 to 12months after ON onset
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model. This model was finally visualized in a nomogram.
Instructions on how to use the nomograms are de-
scribed in the Appendix.
Discussion
Intrathecal biomarkers for inflammation and neurodegen-
eration may become useful for predicting the diagnosis of
MS at onset of acute ON, an early inflammatory event.
Moreover, they may provide a better understanding of MS
pathogenesis. In this prospective population-based cohort
study of acute ON with a longitudinal clinical follow-up,
we aimed to determine the predictive value of such poten-
tial biomarkers. The main finding was that at acute onset
of ON and prior to treatment, patients who later receive a
diagnosis of MS (i.e., MS-ON) had a significantly different
intrathecal inflammatory profile compared to patients
who remained as ION. MS-ON patients showed higher
levels of CSF leukocytes and higher IgG index, both
correlated with CSF IL-10, TNF-α, CXCL13, and IL-17A
levels, and these patients more frequently had OCBs.
Moreover, patients developing MS-ON had progres-
sively increasing levels of NF-L, a marker of neuronal
damage. These data suggest that dynamic immune pro-
cesses are evolving in these patients at ON onset. Poten-
tially, these early indicators can be used to predict
development of MS. Furthermore, the relatively high
predictive power of routine biomarkers (OCB, CSF leu-
kocytes, and IgG index, optimism-corrected ROC area
of 0.82) and candidate biomarkers (CSF IL-10, CXCL13,
and NF-L, optimism-corrected ROC area of 0.87)
suggests these combinations may differentiate MS-ON
from ION. To provide a diagnostic tool, nomograms for
estimation of a patient’s specific risk of MS diagnosis
based on the CSF routine or candidate biomarkers were
developed. Such calculations suggest a potential useful-
ness of composite indices to advance diagnosis, which
could be implemented in clinical practice. The potential
for identifying those patients who later develop MS would
facilitate timely treatment and thus prevent or minimize
disability and other consequences of delayed diagnosis.
CSF examination is invaluable in the diagnostic
work-up of patients with suspected MS. The recent 2017
MS criteria include the presence of CSF-restricted OCBs
in patients presenting with a clinically isolated syndrome
(CIS) together with MRI lesions disseminated in space
[7, 20]. CSF-restricted OCBs substitute for the require-
ment of additional symptoms (a second clinical event)
or lesions disseminated in time to confirm the diagnosis
of MS, based on evidence that these CSF-restricted
OCBs are an independent risk factor for the develop-
ment of MS [20, 21]. CSF examination may identify new
biomarkers that predict MS at an early clinical presenta-
tion. In the current study, we evaluated CSF cytokine/
chemokine levels and routine biomarkers in the acute
phase of ON before treatment with corticosteroids. Our
findings are congruent with the recent attention directed
toward importance of CSF examination, including as-
sessment of the leukocyte numbers and IgG index. We
did not find additional predictive value of an abnormal
CSF leukocyte count and IgG index. However, in the ab-
sence of OCBs, which in general occurs in a limited pro-
portion of cases, IgG index may be of value as a
parameter for intrathecal antibody synthesis [7]. Besides
their clinical implications, the findings here are of bio-
logical relevance since they suggest areas for further in-
terrogation into disease mechanisms. Elevated CSF
levels of CXCL13 in MS-ON compared to ION and con-
trols, together with OCB positivity and IgG index,
strongly suggest B cell activity in the CNS [22]. In-
creased IL-10, an important anti-inflammatory and im-
munosuppressive cytokine, plays an important role in
many inflammatory diseases [23, 24]. However, it is
A
B
Fig. 4 Increased cerebrospinal fluid neurofilament light chain (NF-L)
levels in patients who progress to multiple sclerosis. a Levels of
intrathecal NF-L and b significant correlation of NF-L levels in multiple
sclerosis (MS)-related optic neuritis (ON) patients with cerebrospinal fluid
(CSF) sampling delay from symptom onset. Open circles indicate patients
that were diagnosed with multiple sclerosis 3 to 12months after optic
neuritis onset. Excluded from analysis are two samples due to few data
points in this time interval
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unclear what specific role IL-10 plays in MS. Some aspects
of IL-10 actions are relevant to B cell behavior in MS, but
its involvement may be through other cell types as well
[25, 26]. TNF-α is also upregulated in MS-ON. It
possesses pro-inflammatory properties and is dysregulated
in many systemic and neurologic autoimmune diseases. In
MS, TNF-α is upregulated in active brain lesions and in
CSF [27]. Although TNF-α is generally considered
pro-inflammatory and thus intuitively detrimental in MS,
its impact depends on the particular receptor with which
it interacts. Two TNF-α receptors (TNFR1 and TNFR2)
are expressed by neurons directly and seem to mediate
largely opposing effects with respect to direct de- and
re-myelination of neurons [27]. Thus, it may represent a
double-edged sword in the context of MS due to multiple
mechanisms of action.
NF-L levels in CSF are used as an indicator of neur-
onal damage in the CNS [28]. We found NF-L levels in
CSF to be increased in acute ON patients. This finding
suggests that damage of neuronal tissues occurs closely
to clinical onset [29]. Moreover, NF-L levels significantly
increased over time in MS-ON patients between days 7
and 14 after ON onset, suggesting that neuronal damage
develops progressively over days or weeks in patients
who later develop MS. Collectively, CSF biomarkers
reflect immune dysfunction in MS and in this manner
predict the development of MS.
Risk evaluation is crucial for the selection of therapy at
an early stage of MS. Few studies have evaluated CSF bio-
marker profiles at the acute onset of ON to attempt predic-
tion of risk for subsequent development of MS. In the














AUC = 0.86 [0.74-1]
AUC = 0.89 [0.77-1]
Fig. 5 Receiver-operating characteristic (ROC) for models predicting the conversion of optic neuritis to multiple sclerosis. ROC curves showing the
discriminative performance of our prediction models. ROC curves for logistic regression models comprising levels of IgG index, cerebrospinal fluid
(CSF) leukocytes, and oligoclonal band status, denoted as “routine biomarkers” (green) and CSF IL-10, CXCL13, and NF-L, denoted as “candidate
biomarkers” (apricot). Given is area under curve (AUC) and 95% confidence intervals
Table 2 Multivariate logistic regression modeling for the candidate and routine biomarkers and a combined biomarker model,
which combines candidate and routine biomarkers into one model













38 16.33 0.0010 0.16 0.86 0.86 0.74–0.98
Full model 33 21.53 0.0015 0.10 0.66 0.90 0.78–1.00
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tools based on levels of CSF biomarkers (routine or candi-
date models) which may be useful in estimating this risk
(Fig. 6a, b). For each, three single predictor variables were
compiled into a multivariate logistic model. This study was
based on a small cohort; nonetheless, this cohort was
pre-defined from an epidemiological study with a natural
history and longitudinal follow-up of patients. The
proposed nomograms may benefit from validation in large,
multicenter trials.
A notable strength of this study design is the diagnostic
algorithm used to prospectively assess a population-based
cohort of ON with a high representativity, which has been
A
B
Fig. 6 Nomograms for a routine and b candidate biomarker prediction models for estimation of the patient-specific risk of multiple sclerosis.
Each of the nomograms can estimate a patient’s risk of multiple sclerosis (MS) diagnosis. Instructions for use (here exemplified for the “routine
model”): Locate the patient’s IgG index value on the “IgG index” scale and find the corresponding point score straight above on the “Points”
scale. Do this for the other axes and sum the total point score. Locate the total score on the “Total Points” axis and draw a line straight down on
the “Risk for MS” axis: This is the patient’s estimated risk of MS diagnosis within the first year from onset of optic neuritis (ON). Risk of MS should
be considered with an uncertainty of up to ± 10% for the “routine biomarker” model, and ± 15% for the “candidate biomarker” model according
to calibration plots (Additional file 3: Figure S3). Example of patient from this study: a A patient had no OCBs, 3 leukocytes/μl, and an IgG index of
0.48, giving a score on the “routine biomarker” nomogram of 0, 1, and 9 points, respectively (10 in total). This corresponds to approximately 13%
risk of developing MS. b This same patient had CSF measurements of 0.16 pg/ml IL-10, ≤ 10 pg/ml CXCL13, and 229 pg/ml NF-L. This scored 6, 0,
and 2 points, respectively, and 18 in total on the “candidate biomarker” nomogram. Such a score corresponds to circa 19% risk of MS. This patient
indeed had ION by the end of the follow-up period
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characterized extensively [14]. Laboratory investigations
were performed using largely automated techniques,
which strengthen data reliability. To our knowledge, this
is the first study quantifying an array of CSF cytokines on
the ultra-sensitive Simoa™ platform, which added high
resolution in the low-expressing individuals (limit of
detection in the range of ~ 0.01–0.002 pg/ml).
Conclusions
In conclusion, we determined the predictive value of
CSF biomarkers for MS development in this prospect-
ive population-based study of acute ON. We found a
potential for routine as well as candidate model bio-
markers to differentiate individuals, who would subse-
quently develop MS-ON from those who continued to
manifest ION during follow-up. These findings suggest
that MS-ON patients had strong and highly orchestrated
immune processes occurring in the CNS associated with
early neuronal damage. We took advantage of both routine
and candidate biomarkers to generate two nomograms as
tools for predicting a patient’s specific MS risk after onset
of acute ON. Additional studies with larger, well-designed
cohorts including differential diagnoses and other ethnici-
ties will be needed for validation preferably at multiple
centers.
Appendix
Instructions on how to use nomograms are provided in
the Fig. 6 legend.
As an example, using the “candidate biomarker”
nomogram, one patient had 0.40 pg/ml IL-10, so draw
a line straight up onto Points axis (top axis) to find
the patient’s point. As located on the IL-10 axis, the
patient will receive 20 points. Repeat this procedure
for the CXCL13 and NF-L: Based on the CXCL13
level of 79.2 pg/ml and NF-L of 698.4 pg/ml, the pa-
tient will receive 14 and 8 points, respectively. The
reader may then sum the points achieved for each
biomarker, which in this case is 20 + 14 + 8 = 42
points, and locate this sum on the Total Points axis
(second from the bottom). Draw a line straight down
from the Total Points axis to “Risk for MS” scale
(bottom) to find the patient’s risk for MS. Here, 42
points correspond to 0.85, so this patient’s estimated
risk of MS is 85% (Fig. 6).
The same patient was OCB positive and had 51 leu-
kocytes/μl and IgG index of 1.3. On the routine bio-
marker nomogram, this would give 22, 22, and 24
points, respectively, and 68 in total on the Total Points
axis. This corresponds to circa 83% risk of MS. This
patient indeed was diagnosed with MS closely after
acute ON.
Additional files
Additional file 1: Figure S1. Correlation between intrathecal markers in
isolated optic neuritis. This figure depicts the same, albeit much weaker
or even absent correlations as shown for patients who later converted to
multiple sclerosis (MS-ON) in Fig. 4. (PDF 123 kb)
Additional file 2: Table S1. Logistic regression analyses for single
predictors. Highlighted in bold are p values for which the odds ratio
(OR) confidence interval do not overlap the value of 1, as an indicator of
association between the highlighted markers and MS-ON. The optimal cutoff
value and corresponding sensitivity/specificity is also given. (DOCX 17 kb)
Additional file 3: Figure S2. Receiver-operating characteristic (ROC)
curves for the six individual predictors that were unified in two models in
Fig. 5. (PDF 142 kb)
Additional file 4: Figure S4. Receiver-operating characteristic (ROC) for
models predicting the conversion of optic neuritis to multiple sclerosis
(here for leukocytes and OCBs). Area under ROC curve = 0.8620. (PDF 38 kb)
Additional file 5: Figure S5. Receiver-operating characteristic (ROC) for
models predicting the conversion of optic neuritis to multiple sclerosis
(here for leukocytes and IgG index). Area under ROC curve = 0.8423.
(PDF 38 kb)
Additional file 6: Figure S3.(A + B) Calibration plots for the prediction
models presented as nomograms. The calibration plots assess the
agreement between observations and predictions. For a well-calibrated
prediction model, if a 10% risk for MS is predicted, the observed fre-
quency of MS should be close to 10% amongst all patients with the same
prediction. The apparent calibration curve relies on our original data and
a bias-corrected (=optimism-corrected) curve was based on 500 boot-
strap samples. (PDF 81 kb)
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